Bone-seeking radiopharmaceuticals for treatment of osseous metastases, part 1: α therapy with 223Ra-dichloride

Journal of Nuclear Medicine

Volumn 55, Issue 2, 2014, Pages 268-274

  Pandit Taskar, Neeta ^a   Larson, Steven M ^a   Carrasquillo, Jorge A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bone; Oncology; Radionuclide therapy

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; LEXIDRONAM SAMARIUM SM 153; RADIUM CHLORIDE RA 223; STRONTIUM CHLORIDE SR 89; ANTINEOPLASTIC AGENT; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE; STRONTIUM; STRONTIUM CHLORIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ALPHA RADIATION; ANALGESIA; ANEMIA; APLASTIC ANEMIA; ARTICLE; BONE DISEASE; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DOSIMETRY; DOWN REGULATION; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG USE; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; RADIOISOTOPE DECAY; RISK BENEFIT ANALYSIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ANIMAL; BONE; BONE TUMOR; METASTASIS; METHODOLOGY; NEOPLASM; ONCOLOGY; PATHOLOGY; RADIOMETRY; RADIONUCLIDE THERAPY; REVIEW;

BONE; ONCOLOGY; RADIONUCLIDE THERAPY;

ALPHA PARTICLES; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN MANAGEMENT; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RADIUM; STRONTIUM;

EID: 84897939554     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.112482     Document Type: Article

References (39)

1. Parfitt AM. Bone remodeling, normal and abnormal: a biological basis for the understanding of cancer-related bone disease and its treatment. Can J Oncol. 1995;5(suppl 1): 1-10.
2. Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem. 1999;45: 1353-1358.
3. Theriault RL. Biology of bone metastases. Cancer Control. 2012;19: 92-101.
4. Cancer Pain Relief: With a Guide to Opioid Availability. 2nd ed. Geneva, Switzerland: World Health Organization; 1996: 36-37.
5. Stjernswärd J. WHO cancer pain relief programme. Cancer Surv. 1988;7: 195-208.
6. Adult cancer pain, version 2.2013. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician-gls/pdf/pain.pdf. Published May 29, 2013. Accessed November 15, 2013.
7. Arcangeli G, Giovinazzo G, Saracino B, D'Angelo L, Giannarelli D, Micheli A. Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys. 1998;42: 1119-1126.
8. Spencer S, Marini BL, Figg WD. Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. Anticancer Res. 2012;32: 2391-2398.
9. Crook J. Radiation therapy and radio-nuclides for palliation of bone pain. Urol Clin North Am. 2006;33: 219-226.
10. Hamdy NA, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med. 2001;31: 62-68.
11. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48: 678-686.
12. Parker C, Heinrich D, Helle SI, et al. Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: a phase III randomized trial (ALSYMPCA). Eur Urol Suppl. 2012;11: E130-U523.
13. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alphaemitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11: 4451-4459.
14. Nilsson S, Franzen L, Parker C, et al. Bone-Targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8: 587-594.
15. Larsen RH, Saxtorph H, Skydsgaard M, et al. Radiotoxicity of the alpha-emitting bone-seeker Ra-223 injected intravenously into mice: histology, clinical chemistry and hematology. In Vivo. 2006;20: 325-331.
16. Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting Ra-223: comparison with the beta-emitter Sr-89 in mice. J Nucl Med. 2003;44: 252-259.
17. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting Ra-223 demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62: 3120-3125.
18. Henriksen G, Hoff P, Alstad J, Larsen RH. Ra-223 for endoradiotherapeutic applications prepared from an immobilized Ac-227/Th-227 source. Radiochimica Acta. 2001;89: 661-666.
19. Sgouros G, Roeske JC, McDevitt MR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51: 311-328.
20. Hobbs RF, Song H,Watchman CJ, et al. A bone marrow toxicity model for Ra-223 alpha-emitter radiopharmaceutical therapy. Phys Med Biol. 2012;57: 3207-3222.
21. Neuman WF, Hursh JB, Boyd J, Hodge HC. On the mechanism of skeletal fixation of radium. Ann N Y Acad Sci. 1955;62: 125-136.
22. Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40: 1384-1393.
23. Nilsson S, Franzen L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase ii study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer. 2013;11: 20-26.
24. Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dosefinding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63: 189-197.
25. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369: 213-223.
26. Hindorf C, Chittenden S, Aksnes AK, Parker C, Flux GD. Quantitative imaging of Ra-223-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun. 2012;33: 726-732.
27. Sonpavde G, Pond GR, Berry WR, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012;30: 607-613.
28. Lassmann M, Nosske D. Dosimetry of Ra-223-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40: 207-212.
29. Xofigo product information. U.S. Xofigo Web site. www.xofigo-us.com/ productinformation. Accessed November 18, 2013.
30. Wiseman GA, Dispensieri A, Lacy MQ, Gertz MA. High dose samarium-153 EDTMP (ethylenediaminetetramethylene phosphonic acid) and Melphalan chemotherapy with peripheral blood stem cell rescue for therapy of patients with multiple myeloma: phase I and II clinical trial preliminary results [abstract]. J Nucl Med. 2003;44(suppl): 174P.
31. Dispenzieri A, Wiseman GA, Lacy MQ, et al. A phase I study of Sm-153-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia. 2005;19: 118-125.
32. Morris MJ, Pandit-Taskar N, Carrasquillo J, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27: 2436-2442.
33. Tu SM, Kim J, Pagliaro LC, et al. Strontium-89 combined with chemotherapy does not compromise subsequent therapy in selected patients with androgenindependent prostate cancer. J Clin Oncol. 2005;23: 7904-7910.
34. Tu SM, Kim J, Pagliaro LC, et al. Long-Term effects of strontium-89 combined with chemotherapy in patients with androgen-independent prostate cancer and bone metastases [abstract]. J Clin Oncol. 2005;23(suppl): 420S.
35. Tu SM, Kim J, Pagliaro LC, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005;23: 7904-7910.
36. Ricci S, Boni G, Pastina I, et al. Clinical benefit of bone-Targeted radiometabolic therapy with Sm-153-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34: 1023-1030.
37. Amato RJ, Hernandez-McClain J, Henary H. Bone-Targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Am J Clin Oncol. 2008;31: 532-538.
38. Suttmann H, Grgic A, Lehmann J, et al. Combining Sm-153-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience. Cancer Biother Radiopharm. 2008;23: 609-618.
39. 223Ra dichloride against skeletal metastases in patients with prostate cancer. Health Phys J. In press.